Register
Login:
Share:
Email Facebook Twitter

Share Views: HUM CEO updates on Yanfolila and Dugbe Gold Projects. Watch here

Share Views Ep. 19
HUM CEO updates on Yanfolila and Dugbe Gold Projects.


BTG Share Chat (BTG)



Share Price: 571.00Bid: 571.00Ask: 571.50Change: 0.00 (0.00%)No Movement on Btg
Spread: 0.50Spread as %: 0.09%Open: 567.50High: 574.00Low: 565.00Yesterday’s Close: 571.00


Share Discussion for BTG


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Overman
Posts: 1,697
Off Topic
Opinion:No Opinion
Price:570.50
RE: Down down deeper and down....
Fri 15:55
Take over would be nice
 
Rollon
Posts: 6
Observation
Opinion:No Opinion
Price:568.00
Down down deeper and down....
Fri 11:17
Well, it certainly looks like Louise and Rolf know the right time to sell their share options dunnit eh?

Quiet 'ere innit?
4PetesSake
Posts: 4,427
Off Topic
Opinion:No Opinion
Price:611.50
RNS - Half Year Report
15 Nov '16
CEO Summary
Louise Makin, BTG's CEO, commented: "The business has performed well during the first half, and the outlook for the full year is strong. We have the capabilities and financial strength to take advantage of the increasing opportunities we are seeing to expand our Interventional Medicine business. By accelerating our growth strategy through reinvestment of our cash flows to maximise the value of and expand the current portfolio, we can build leadership positions in selected areas of interventional medicine and thereby create sustainable value for shareholders."

Outlook
BTG has performed well in the first half, with double-digit revenue growth, strong free cash flow and disciplined cost control. Through the acquisition of Galil Medical we have strengthened our portfolio, capabilities and leadership in Interventional Medicine, which is our fastest growing and highest revenue business. We have the resources and capabilities to capitalise on the expanding opportunities we see in Interventional Medicine, by reinvesting our strong cash flows into further commercial expansion, pipeline development and acquisitions. In this way we will deliver double-digit compound annual revenue growth, cement our leadership in our chosen Interventional Medicine markets and create significant value for shareholders.

In view of the above, it was perhaps surprising to see the SP down over 5% today.
maddmax
Posts: 87
Observation
Opinion:Hold
Price:630.00
Price Drop.
1 Nov '16
Falling two weeks before results, hmmm interesting.
jumbo89
Posts: 106
Off Topic
Opinion:No Opinion
Price:658.00
Silence
31 Oct '16
Quiet 'ere innit?
jumbo89
Posts: 106
Off Topic
Opinion:No Opinion
Price:619.50
new chat format
25 Aug '16
Not a fan.
Btg is no great shakes either
Rollon
Posts: 6
Observation
Opinion:No Opinion
Price:661.50
More gravy
26 Jul '16
Re: RNS Number : 9186E, BTG PLC, 21 July 2016:
Louise and Rolf cash in another �900k+ worth of shares between them on 18th July. Nice.

When are the BOD going to issue a dividend???
bretty
Posts: 54
Off Topic
Opinion:No Opinion
Price:681.00
Currency
20 Jul '16
Share prices are forward indicators. BTG may be hedged but future hedges will be at 1.30 or possibly even lower. Is it £13M in earnings per 5c, do I recall? At 1.30; this stock must have a long way to run, albeit with earnings realization a little way down the track. Just dipping in with a further £30k.
Walkley
Posts: 1,152
Observation
Opinion:No Opinion
Price:645.50
price drop
14 Jul '16
AGM statement said wouldn't gain much from pound drop immediately as currency sold forward. Share price drop somewhat overdone IMO.
Sundancer8
Posts: 33
Off Topic
Opinion:No Opinion
Price:646.00
assistance
14 Jul '16
Thank you Jumbo. Much appreciated. Seems so silly when loads of buys at £1m are going through in the evenings!
Best Wishes and thanks again.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.